Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine Acetate Long-term Safety in Pediatric POS
NCT03108729Phase 3Withdrawn
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eslicarbazepine acetate in focal onset seizure, sponsored by Sumitomo Pharma America. Planned start Jul 2017; status: withdrawn.
02
Drugs
eslicarbazepine acetate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT03108729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108729.